(The composite of gallbladder or biliary diseases incorporated cholelithiasis, cholecystitis, other gallbladder disorders, and biliary diseases.) Results: A total of nine trials with 9871 participants (6828 in the tirzepatide group and 3043 in the control group) that met the pre-specified criteria were included
Bariatric surgery remains an option for patients with severe obesity who meet specific NICE criteria generally a BMI of 40 or above, or 35 or above with significant comorbidities, with lower thresholds applicable in some groups, such as those with recent-onset type 2 diabetes
Dehydration on GLP-1: What Could Be Causing It
NAD+ helps maintain proper blood flow to brain activity through neurovascular coupling
Tirzepatide dosing follows its own escalation schedule: 2.5 mg for weeks 1 through 4, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg at maintenance
10.1007/s13770-018-0118-x 11 FoordS